Bahlis NJ et al. Elranatamab in relapsed or refractory multiple myeloma: The MagnetisMM-1 phase 1 trial. Nat Med 2023;29(10):2570-76. Abstract

Bar N et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-cell maturation antigen (BCMA) x CD3 T-cell engager (TCE), administered subcutaneously (sc) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated results from a phase 1 first‑in‑human clinical study. ASH 2023;Abstract 2011.

Cliff ERS et al. Acknowledging infection risk in bispecific antibody trials in the treatment of multiple myeloma. J Clin Oncol 2023;41(10):1949-51. Abstract

Lee HC et al. LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma. ASCO 2023;Abstract 8006.

Lesokhin AM et al. Elranatamab in relapsed ore refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results. Nat Med 2023;29(9):2259-67. Abstract

Markouli M et al. Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: Pathogenesis, prevention and management. Curr Oncol 2023;30(7):6330-52. Abstract

Matous JV et al. Talquetamab + pomalidomide in patients with relapsed/refractory multiple myeloma: Safety and preliminary efficacy results from the phase 1b MonumenTAL-2 study. ASH 2023;Abstract 1014.

Schinke CD et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM). J Clin Oncol 2023;41(16_suppl):8036. Abstract

Soltantabar P et al. Impact of treatment modality and route of administration on cytokine release syndrome in relapsed or refractory multiple myeloma: A meta-analysis. Clin Pharmacol Ther 2024;115(6):1258-68. Abstract